NASDAQ: AIXCAixcrypto Holdings Inc Stock
$2.50-0.13 (-4.94%)
Updated Dec 5, 2025
AIXC Price
$2.50
Fair Value Price
$3.25
Market Cap
$12.90M
52 Week Low
$1.61
52 Week High
$8.81
P/E
-20.83x
P/B
0.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$7M
Beta
0.69
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AIXC Overview
AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AIXC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important AIXC news, forecast changes, insider trades & much more!
AIXC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AIXC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIXC ($2.50) is undervalued by 23.04% relative to our estimate of its Fair Value price of $3.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AIXC ($2.50) is significantly undervalued by 23.04% relative to our estimate of its Fair Value price of $3.25 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AIXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AIXC due diligence checks available for Premium users.
Valuation
AIXC fair value
Fair Value of AIXC stock based on Discounted Cash Flow (DCF)
Price
$2.50
Fair Value
$3.25
Undervalued by
23.04%
AIXC ($2.50) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AIXC ($2.50) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AIXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AIXC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-20.83x
Industry
186.51x
Market
46.7x
AIXC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.33x
Industry
5.29x
AIXC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIXC's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.9M
Profit Margin
0%
AIXC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$43.5M
Liabilities
$4.9M
Debt to equity
0.13
AIXC's short-term assets ($43.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIXC's short-term assets ($43.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIXC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIXC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
-$291.0k
Financing
$40.9M
AIXC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIXC vs Biotech Stocks
Aixcrypto Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.